Advertisement

Topics

Realm Therapeutics completes enrolment in Phase 2 atopic dermatitis treatment study

10:17 EDT 24 May 2018 | FinanzNachrichten

Clinical-stage biopharmaceutical company Realm Therapeutics has completed enrollment in its Phase 2 study of PR022 - its topical IL-4 / IL-13 inhibitor for the treatment of atopic dermatitis - it a...

Original Article: Realm Therapeutics completes enrolment in Phase 2 atopic dermatitis treatment study

NEXT ARTICLE

More From BioPortfolio on "Realm Therapeutics completes enrolment in Phase 2 atopic dermatitis treatment study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...